Table 1 Patient demographics, disease characteristics and clinical manifestations of PFS patients at canakinumab initiation
Characteristics | Overall (N=147) | Children (N=68) | Adults (N=79) | PFS subtypes | |||
|---|---|---|---|---|---|---|---|
CAPS (N=59) | TRAPS (N=40) | HIDS/MKD (N=11) | FMF (N=42) | ||||
Age (years), mean (SD) | 21.7 (16.1) | 9.9 (4.5) | 31.9 (15.6) | 24.0 (18) | 21.4 (14.6) | 20.6 (9.8) | 18.2 (12.4) |
Female, n (%) | 63 (42.9) | 28 (41.2) | 35 (44.3) | 23 (39.0) | 18 (45.0) | 6 (54.5) | 19 (45.2) |
Body mass-index (for adults only; kg/m2), mean (SD) | 24.9 (5.6) [N=62] | - | 24.9 (5.6) [N=62] | 27.3 (5.9) [N=25] | 24.0 (6) [N=19] | 25.0 ± 4.8 [N=3] | 22.1 ± 2.9 [N=16] |
Race/ethnicity, n (%) | |||||||
White/Non-Hispanic | 103 (70.1) | 40 (58.8) | 63 (79.7) | 46 (78.0) | 29 (72.5) | 7 (63.6) | 25 (59.5) |
Hispanic | 23 (15.6) | 11 (16.2) | 12 (15.2) | 10 (16.9) | 6 (15.0) | 2 (18.2) | 6 (14.3) |
Asian/Pacific Islander | 8 (5.4) | 7 (10.3) | 1 (1.3) | 1 (1.7) | 1 (2.5) | 2 (18.2) | 4 (9.5) |
Black/Non-Hispanic | 7 (4.8) | 6 (8.8) | 1 (1.3) | 2 (3.4) | 4 (10.0) | 0 (0.0) | 1 (2.4) |
Other | 6 (4.1) | 4 (5.9) | 2 (2.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (14.3) |
Insurance type, n (%) | |||||||
Commercial/private | 127 (86.4) | 59 (86.8) | 68 (86.1) | 51 (86.4) | 38 (95.0) | 9 (81.8) | 32 (76.2) |
Medicare | 15 (10.2) | 8 (11.8) | 7 (8.9) | 4 (6.8) | 2 (5.0) | 2 (18.2) | 8 (19.0) |
Medicaid | 7 (4.8) | 3 (4.4) | 4 (5.1) | 4 (6.8) | 2 (5.0) | 1 (9.1) | 1 (2.4) |
Military | 2 (1.4) | 2 (2.9) | 0 (0.0) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 2 (4.8) |
Other (i.e., Tricare) | 1 (0.7) | 0 (0.0) | 1 (1.3) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Primary medical specialty of the physician who prescribed canakinumab, n (%) | |||||||
Rheumatology | 48 (32.7) | 21 (30.9) | 27 (34.2) | 21 (35.6) | 10 (25.0) | 3 (27.3) | 14 (33.3) |
Dermatology | 46 (31.3) | 23 (33.8) | 23 (29.1) | 18 (30.5) | 14 (35.0) | 5 (45.5) | 11 (26.2) |
Immunology | 31 (21.1) | 18 (26.5) | 13 (16.5) | 14 (23.7) | 3 (7.5) | 3 (27.3) | 13 (31.0) |
Allergy | 22 (15.0) | 6 (8.8) | 16 (20.3) | 6 (10.2) | 13 (32.5) | 0 (0.0) | 4 (9.5) |
Primary subspecialty of the physician who prescribed canakinumab, n (%) | |||||||
Adult | 79 (53.7) | 23 (33.8) | 56 (70.9) | 33 (55.9) | 22 (55.0) | 3 (27.3) | 25 (59.5) |
Pediatrics | 68 (46.3) | 45 (66.2) | 23 (29.1) | 26 (44.1) | 18 (45.0) | 8 (72.7) | 17 (40.5) |
Disease duration (years) from first diagnosis to canakinumab initiation, mean (SD) | 5.2 (6.2) | 3.0 (2.5) | 7.1 (7.6) | 6.3 (6.7) | 3.9 (4.2) | 6.7 (8.5) | 4.7 (5.9) |
PFS severity, n (%) | |||||||
Mild | 33 (22.4) | 20 (29.4) | 13 (16.5) | 10 (16.9) | 12 (30) | 5 (45.5) | 6 (14.3) |
Moderate | 102 (69.4) | 45 (66.2) | 57 (72.2) | 44 (74.6) | 25 (62.5) | 6 (54.5) | 31 (73.8) |
Severe | 12 (8.2) | 3 (4.4) | 9 (11.4) | 5 (8.5) | 3 (7.5) | 0 (0.0) | 5 (11.9) |
Number of attacks/flares per year, n (%) | |||||||
<1 | 7 (4.8) | 5 (7.4) | 2 (2.5) | 5 (8.5) | 0 (0.0) | 0 (0.0) | 2 (4.8) |
1-3 | 50 (34.0) | 19 (27.9) | 31 (39.2) | 20 (33.9) | 18 (45.0) | 4 (36.4) | 8 (19.0) |
4-6 | 64 (43.5) | 29 (42.6) | 35 (44.3) | 22 (37.3) | 15 (37.5) | 6 (54.5) | 24 (57.1) |
7-12 | 20 (13.6) | 11 (16.2) | 9 (11.4) | 8 (13.6) | 7 (17.5) | 1 (9.1) | 5 (11.9) |
>12 | 4 (2.7) | 2 (2.9) | 2 (2.5) | 2 (3.4) | 0 (0.0) | 0 (0.0) | 3 (7.1) |
Unknown | 2 (1.4) | 2 (2.9) | 0 (0.0) | 2 (3.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Average duration of attacks/flares, n (%) | |||||||
<1 day | 14 (9.5) | 7 (10.3) | 7 (8.9) | 4 (6.8) | 4 (10.0) | 3 (27.3) | 3 (7.1) |
1-3 days | 62 (42.2) | 29 (42.6) | 33 (41.8) | 29 (49.2) | 18 (45.0) | 2 (18.2) | 16 (38.1) |
4-7 days | 54 (36.7) | 23 (33.8) | 31 (39.2) | 18 (30.5) | 12 (30.0) | 6 (54.5) | 20 (47.6) |
>7 days | 10 (6.8) | 3 (4.4) | 7 (8.9) | 3 (5.1) | 6 (15.0) | 0 (0.0) | 1 (2.4) |
Unknown | 7 (4.8) | 6 (8.8) | 1 (1.3) | 5 (8.5) | 0 (0.0) | 0 (0.0) | 2 (4.8) |
PFS clinical manifestations at canakinumab initiation, n (%) | |||||||
Fever | 116 (78.9) | 57 (83.8) | 59 (74.7) | 41 (69.5) | 33 (82.5) | 8 (72.7) | 38 (90.5) |
Fatigue/malaise | 84 (57.1) | 36 (52.9) | 48 (60.8) | 30 (50.8) | 20 (50.0) | 8 (72.7) | 28 (66.7) |
Skin/cutaneous | 84 (57.1) | 36 (52.9) | 48 (60.8) | 30 (50.8) | 20 (50.0) | 8 (72.7) | 28 (66.7) |
Musculoskeletal | 74 (50.3) | 31 (45.6) | 43 (54.4) | 27 (45.8) | 19 (47.5) | 6 (54.5) | 26 (61.9) |
Gastrointestinal | 42 (28.6) | 22 (32.4) | 20 (25.3) | 12 (20.3) | 9 (22.5) | 6 (54.5) | 16 (38.1) |
Mood/behavior | 25 (17.0) | 12 (17.6) | 13 (16.5) | 13 (22.0) | 7 (17.5) | 0 (0.0) | 6 (14.3) |
Neurological | 9 (6.1) | 6 (8.8) | 3 (3.8) | 4 (6.8) | 2 (5.0) | 0 (0.0) | 3 (7.1) |
Ocular | 7 (4.8) | 2 (2.9) | 5 (6.3) | 4 (6.8) | 1 (2.5) | 1 (9.1) | 1 (2.4) |
Lymphoid organs | 5 (3.4) | 1 (1.5) | 4 (5.1) | 2 (3.4) | 0 (0.0) | 2 (18.2) | 1 (2.4) |
Cardiorespiratory/circulatory organ | 4 (2.7) | 2 (2.9) | 2 (2.5) | 2 (3.4) | 1 (2.5) | 0 (0.0) | 1 (2.4) |
Genitourinary | 3 (2.0) | 1 (1.5) | 2 (2.5) | 2 (3.4) | 0 (0.0) | 0 (0.0) | 1 (2.4) |
Complications of PFS | 1 (0.7) | 1 (1.5) | 0 (0.0) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Othera | 1 (0.7) | 1 (1.5) | 0 (0.0) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
None of the above | 12 (8.2) | 7 (10.3) | 5 (6.3) | 6 (10.2) | 4 (10.0) | 0 (0.0) | 2 (4.8) |